Patents by Inventor David J. Donnelly

David J. Donnelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190282714
    Abstract: The present invention relates to radiolabeled IDO1 inhibitors or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of IDO enzymes in mammals.
    Type: Application
    Filed: July 18, 2017
    Publication date: September 19, 2019
    Inventors: David J. Donnelly, Erin Lee Cole, Richard Charles Burrell, Wesley A. Turley, Alban J. Allentoff, Michael Arthur Wallace, James Aaron Balog, Audris Huang, Mette Skinbjerg
  • Publication number: 20190117801
    Abstract: The invention relates to the synthesis and use of 18F-labeled millamolecules for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
    Type: Application
    Filed: May 17, 2017
    Publication date: April 25, 2019
    Inventors: David J. Donnelly, Kenneth M. Boy, Yunhui Zhang, Joonyoung KIM, Adrienne Pena
  • Patent number: 9987381
    Abstract: The present invention relates to radiolabeled LPA1 receptor antagonists or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of LPA1 receptors in mammals.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: June 5, 2018
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, YALE UNIVERSITY
    Inventors: Thomas Jon Seiders, David J. Donnelly, Samuel J. Bonacorsi, Jr., Kai Cao, Tritin Tran, Adrienne Pena, Joonyoung Kim, Richard E. Carson, Nabeel Nabulsi, Jean-Dominique Gallezot, Yiyun Huang, Jeffrey Roger Roppe
  • Publication number: 20170217896
    Abstract: The present invention relates to a method of preparing Cabozantinib (Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide(4-fluoro-phenyl)amide) and 18F labeled Cabozantinib.
    Type: Application
    Filed: July 31, 2015
    Publication date: August 3, 2017
    Inventors: Wei XU, David J. Donnelly, Patrick L. Chow, Benjamin J. Henley
  • Publication number: 20160256577
    Abstract: The present invention relates to radiolabeled LPA1 receptor antagonists or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of LPA1 receptors in mammals.
    Type: Application
    Filed: October 31, 2014
    Publication date: September 8, 2016
    Inventors: Thomas Jon Seiders, David J. Donnelly, Samuel J. Bonacorsi, JR., Kai Cao, Tritin Tran, Adrienne Pena, Joonyoung Kim, Richard E. Carson, Nabel Nabulsi, Jean-Dominique Gallezot, Yiyun Huang, Jeffrey Roger Roppe
  • Patent number: 8158674
    Abstract: Provided are chalcogenoxanthylium compounds which can effectively be used as sensitizers in photodynamic therapy, virucides in photodynamic antimicrobial chemotherapy and reversal agents of Pgp function in cancer cells. Further provided is a general method for the preparation of chalcogenoxanthylium compounds.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: April 17, 2012
    Assignee: The Research Foundation of State University of New York
    Inventors: Michael R. Detty, David J. Donnelly
  • Publication number: 20110166366
    Abstract: Provided are chalcogenoxanthylium compounds which can effectively be used as sensitizers in photodynamic therapy, virucides in photodynamic antimicrobial chemotherapy and reversal agents of Pgp function in cancer cells. Further provided is a general method for the preparation of chalcogenoxanthylium compounds.
    Type: Application
    Filed: March 11, 2011
    Publication date: July 7, 2011
    Inventors: Michael R. Detty, David J. Donnelly, Stephen J. Wagner
  • Patent number: 7906500
    Abstract: Provided are chalcogenoxanthylium compounds which can effectively be used as sensitizers in photodynamic therapy, virucides in photodynamic antimicrobial chemotherapy and reversal agents of Pgp function in cancer cells. Further provided is a general method for the preparation of chalcogenoxanthylium compounds.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: March 15, 2011
    Assignee: The Research Foundation of State University of New York
    Inventors: Michael R. Detty, David J. Donnelly